(NewsDirect)
Immunic Inc (NASDAQ:IMUX) President andCEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after thebiotechnology company announced the completion of the enrolment of itsphase 2 CALLIPER trial of lead asset vidofludimus calcium (IMU-838),in patients with progressive multiple sclerosis (PMS).
Dr Vitt explains that 467 patients havebeen enrolled across various sub-indications including primaryprogressive, secondary active, and non-active secondary progressiveMS. He calls it a "great day for the programme." The trialaims to assess the efficacy of IMU-838 and Dr. Vitt highlights thefocus on biomarkers, particularly the neurofilament light chain (NFL),a protein indicative of active disease.
Anticipated next stepsinclude an interim analysis set for release this fall, which willexamine biomarker benefits for different sub-indications. Dr. Vittalso reflects on what he considers a successful 2023 so far, withpositive data emerging from Immunic's colitis maintenance andIMU-856 celiac disease programs.
ContactDetails
Proactive United States
+1347-449-0879
Copyright (c) 2023 TheNewswire - All rights reserved.